Pfizer, Valneva Report Topline Results From Phase 3 VALOR Clinical Trial Of Investigational 6-Valent OspA-Based Lyme Disease Vaccine Candidate PF-0730740; Trial Shows More Than 70% Efficacy In Preventing Lyme Disease In Individuals Aged Five Years And Above

Pfizer Inc. and Valneva SE announced topline results from the Phase 3 VALOR clinical trial for their investigational 6-valent OspA-based Lyme disease vaccine candidate PF-07307405, showing more than 70% efficacy in preventing Lyme disease in individuals aged five years and above. The vaccine demonstrated an efficacy of 73.2% from 28 days post-dose 4 and 74.8% from 1-day post-dose 4 compared to the placebo arm. Pfizer plans to submit the results to regulatory authorities, having identified no safety concerns during the trial.